Sugi Predict

Sugi Predict / Compounds / SCHEMBL384682

SCHEMBL384682

SCHEMBL384682

O=S(=O)(Cl)c1cc(F)c(Br)cc1F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.38
▸ HSD11B1 P28845 1/20 0.37
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ NR3C1 P04150 1/20 0.34
▸ KDM1A O60341 4/20 0.33
▸ KDM1B Q8NB78 3/20 0.33
▸ KCNH2 Q12809 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ TRPV4 Q9HBA0 1/20 0.32
▸ CA12 O43570 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CA13 Q8N1Q1 1/20 0.31
▸ HSD17B1 P14061 2/20 0.30
▸ HSD17B2 P37059 2/20 0.30
▸ GPR27 Q9NS67 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29835220 1.00 PKM (0.38) PKMHSD11B1CA1CA2CA9
SCHEMBL1349380 0.91 CA1 (0.35) PKMHSD11B1CA1CA2CA9
SCHEMBL16759572 0.83 TRPV4 (0.38) PKMHSD11B1CA1CA2CA9
SCHEMBL1510826 0.82 CA2 (0.45) PKMHSD11B1CA1CA2CA9
SCHEMBL32680858 0.82 KDM1A (0.40) PKMHSD11B1CA1CA2CA9
SCHEMBL19613829 0.82 POLB (0.37) CA1CA2CA9NPC1TRPV4
SCHEMBL29835175 0.81 SLC1A3 (0.37) PKMCA1CA2TRPV4CA12
SCHEMBL320605 0.81 SLC1A3 (0.37) PKMCA1CA2TRPV4CA12
SCHEMBL3948765 0.79 TRPV4 (0.42) PKMHSD11B1CA1CA2CA9
SCHEMBL2991536 0.79 TRPV4 (0.38) HSD11B1CA1CA2CA9TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 — — EP claimed
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2024-02-27 — — US disclosed
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2024-02-27 — — US disclosed
CN-110885328-B Sulfonamide compounds as sodium channel blockers and uses thereof 成都康弘药业集团股份有限公司 2022-08-12 — — CN disclosed
CN-110885319-B Sulfonamide compounds as sodium channel blockers and uses thereof 成都康弘药业集团股份有限公司 2022-08-12 — — CN disclosed
WO-2022109001-A1 GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2022-05-27 — — WO disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 — — US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 — — US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 — — US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 — — EP disclosed
WO-2002020474-A2 RESORCINOL DERIVATIVES PFIZER PRODUCTS INC. (US) 2002-03-14 — — WO disclosed
WO-2001090094-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO disclosed
WO-2001090091-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO disclosed
US-6300352-B1 FOR THERAPY OF ASTHMA ASTRAZENECA AB (SE) 2001-10-09 — — US disclosed
EP-1115706-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2001-07-18 — — EP disclosed
WO-2000018730-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-04-06 — — WO disclosed
EP-0971892-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Astra Pharmaceuticals Limited (GB) 2000-01-19 — — EP disclosed
WO-1998042670-A1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRA PHARMACEUTICALS LTD. (GB) 1998-10-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 PKM 3945/4885HSD11B1 200/4885CA1 2108/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 PKM 3945/4885HSD11B1 200/4885CA1 2108/4885
US-11912668-B2 GCN2 and perk kinase inhibitors and methods of use thereof EIF2AK4, GCN1, MAPKAPK2 PKM 292/4885HSD11B1 392/4885CA1 4707/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B PKM 4411/4885HSD11B1 697/4885CA1 1628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.